Brokers Issue Forecasts for BBIO Q2 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2026 earnings estimates for BridgeBio Pharma in a note issued to investors on Tuesday, April 15th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.77) for the quarter. HC Wainwright has a "Buy" rating and a $53.00 price objective on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma's Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.98) EPS.

Several other research firms have also issued reports on BBIO. Evercore ISI raised their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a report on Monday, December 23rd. JPMorgan Chase & Co. boosted their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday, March 24th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $95.00 target price on shares of BridgeBio Pharma in a research note on Friday, February 21st. Redburn Atlantic started coverage on BridgeBio Pharma in a report on Monday, March 31st. They set a "buy" rating and a $50.00 price objective for the company. Finally, Scotiabank upped their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, BridgeBio Pharma presently has an average rating of "Moderate Buy" and a consensus price target of $53.00.

BridgeBio Pharma Trading Up 0.2 %

NASDAQ:BBIO traded up $0.07 during midday trading on Wednesday, hitting $33.94. 606,762 shares of the company traded hands, compared to its average volume of 2,264,652. The firm has a market capitalization of $6.46 billion, a P/E ratio of -11.91 and a beta of 1.08. The firm's fifty day moving average is $33.79 and its 200-day moving average is $30.14. BridgeBio Pharma has a 12-month low of $21.62 and a 12-month high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million.

Insiders Place Their Bets

In other news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total value of $197,760,000.00. Following the completion of the transaction, the insider now directly owns 19,260,971 shares of the company's stock, valued at approximately $634,841,604.16. The trade was a 23.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Neil Kumar sold 326,932 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the sale, the chief executive officer now directly owns 5,371,515 shares of the company's stock, valued at approximately $194,932,279.35. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,694,739 shares of company stock worth $327,308,651 in the last three months. Corporate insiders own 24.66% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd acquired a new position in shares of BridgeBio Pharma during the third quarter valued at about $338,000. Barclays PLC grew its stake in BridgeBio Pharma by 31.9% during the 3rd quarter. Barclays PLC now owns 545,008 shares of the company's stock valued at $13,876,000 after purchasing an additional 131,743 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of BridgeBio Pharma by 3.8% in the third quarter. Geode Capital Management LLC now owns 3,413,949 shares of the company's stock worth $86,936,000 after purchasing an additional 123,540 shares during the last quarter. Exome Asset Management LLC boosted its position in BridgeBio Pharma by 167.4% in the third quarter. Exome Asset Management LLC now owns 211,000 shares of the company's stock valued at $5,372,000 after buying an additional 132,093 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company's stock worth $29,155,000 after buying an additional 19,978 shares during the period. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.